Last updated: 2026-10-08 20:39:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Profound Medical Corp. (PROF) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $6.88, with a market capitalization of $222.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.80 to $8.95. This page covers its latest market performance, valuation, price trends and company information.
$222.17M | |
$6.50 | |
$28.97 | |
$3.10 | |
$5.68 | |
2.93M | |
124.00K | |
-- | |
$8.95 | |
$4.80 | |
-- | |
-- |
Profound Medical Corp. (PROF) is trading at $6.88 in after-hours trading as of 2026-10-08 20:37:00, up 21.13% ($1.20) from the regular-session close of $5.68.
After-hours trading shows how investors are pricing PROF after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Profound Medical Corp. (PROF) moved from $5.72 to $6.88, representing a gain of 20.28% ($1.16).
The stock traded between $5.65 and $7.36 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 157.95 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 50.1%
PROF is currently trading at $6.88, placing it 50.1% of the way from its 52-week low of $4.80 to its 52-week high of $8.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 162 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Profound Medical Corp. (PROF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.